Matinas BioPharma announces pricing of $8.0 million public offering
Matinas BioPharma announced pricing of a public offering of up to 8,000 shares of Series B Convertible Preferred Stock, or Series B Preferred, with a stated value of $1,000 per share and convertible into an aggregate of 16,000,000 shares of common stock at a conversion price of $0.50 per share. June 19, 2018